Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) Senior Officer Thomas Heineman acquired 15,000 shares of the business's stock in a transaction dated Thursday, July 17th. The stock was acquired at an average cost of C$1.74 per share, with a total value of C$26,098.50.
Oncolytics Biotech Price Performance
Shares of ONC traded down C$0.04 during midday trading on Friday, hitting C$1.74. The company's stock had a trading volume of 170,908 shares, compared to its average volume of 146,773. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. Oncolytics Biotech Inc. has a one year low of C$0.44 and a one year high of C$2.08. The stock has a market capitalization of C$134.11 million, a price-to-earnings ratio of -4.85 and a beta of 1.35. The company's fifty day simple moving average is C$0.90 and its two-hundred day simple moving average is C$0.95.
Wall Street Analyst Weigh In
Separately, Jones Trading cut Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.
Check Out Our Latest Research Report on ONC
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
